Bolt Biotherapeutics shares are trading lower after the company reported Q1 financial results. Also, multiple firms downgraded their respective price targets on the stock.
Portfolio Pulse from Benzinga Newsdesk
Bolt Biotherapeutics shares are trading lower following the release of their Q1 financial results. Additionally, several firms have downgraded their price targets for the stock.
May 15, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bolt Biotherapeutics shares are experiencing a decline due to disappointing Q1 financial results and multiple firms downgrading their price targets.
The combination of underwhelming Q1 financial results and multiple price target downgrades is likely to negatively impact investor sentiment and drive the stock price lower in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100